{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:37:07Z","timestamp":1792291027418,"version":"4.4.0"},"reference-count":152,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The \u201cangiogenesis switch\u201d\u2014defined as the active process by which solid tumors develop their own circulation\u2014plays an important role in both tumoral growth and propagation. As the malignant tumor grows and reaches a critical size, the metabolic needs as a function of an ever-increasing distance to the nearest emergent blood vessel, can no longer be covered by the microenvironment of the peritumoral tissue. Although a relatively discrete process, the \u201cangiogenic switch\u201d acts as a limiting stage of tumoral development present from the avascular hyperplasia phase to the vascularized neoplastic phase, providing support for tumor expansion and metastasis. Over time, research has focused on blocking the angiogenetic pathways (such as VEGF\/VEGFR signaling axis) leading to the development of targeted therapeutic agents such as Bevacizumab. Objectives: We conducted a review of the molecular principles of tumoral angiogenesis and we tried to follow the history of Bevacizumab from its first approval for human usage 20 years ago to current days, focusing on the impact this agent had in solid tumor therapy. A comprehensive review of clinical trials pertaining to Bevacizumab (from the era of the preclinic trials leading to approval for human usage, to the more recent randomized trial focusing on combination targeted therapy) further details the role of this drug. We aimed to establish if this ancient drug continues to have a place in modern oncology. Conclusions: Bevacizumab, one of the first drugs targeting tumoral microenvironment, remains one of the most important oncologic agents blocking the VEGF\/VEGFR angiogenic pathway. otherwise, history of 20 years marked by numerous controversies (ranging from methodological errors of clinical trials to withdrawal of approval for human usage in breast cancer patients, from discussions about severe side effects to resistance to therapy and limited efficacity), Bevacizumab continues to provide an optimal therapeutic option for many solid tumors that previously had little to no means of treatment, improving otherwise bleak outcomes. Even in the era of personalized precision oncology, Bevacizumab continues to be a key element in many therapeutic regimens both as monotherapy and in combination with newer targeted agents.<\/jats:p>","DOI":"10.3390\/cancers17071126","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T12:41:02Z","timestamp":1743079262000},"page":"1126","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Blocking Tumoral Angiogenesis VEGF\/VEGFR Pathway: Bevacizumab\u201420 Years of Therapeutic Success and Controversy"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9225-8030","authenticated-orcid":false,"given":"Elena","family":"Chitoran","sequence":"first","affiliation":[{"name":"Medicine School, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"General Surgery and Surgical Oncology Department I, Bucharest Institute of Oncology \u201cProf. Dr. Al. Trestioreanu\u201d, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6161-1951","authenticated-orcid":false,"given":"Vlad","family":"Rotaru","sequence":"additional","affiliation":[{"name":"Medicine School, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"General Surgery and Surgical Oncology Department I, Bucharest Institute of Oncology \u201cProf. Dr. Al. Trestioreanu\u201d, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5740-1209","authenticated-orcid":false,"given":"Daniela-Cristina","family":"Stefan","sequence":"additional","affiliation":[{"name":"Medicine School, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4269-4269","authenticated-orcid":false,"given":"Giuseppe","family":"Gullo","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Villa Sofia Cervello Hospital, University of Palermo, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurentiu","family":"Simion","sequence":"additional","affiliation":[{"name":"Medicine School, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"General Surgery and Surgical Oncology Department I, Bucharest Institute of Oncology \u201cProf. Dr. Al. Trestioreanu\u201d, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJM198905043201811","article-title":"Successful Treatment of an Angiogenic Disease","volume":"320","author":"Folkman","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1126\/science.284.5415.808","article-title":"Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice","volume":"284","author":"Bergers","year":"1999","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor Angiogenesis: Therapeutic Implications","volume":"285","author":"Sherwood","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","article-title":"Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis","volume":"86","author":"Hanahan","year":"1996","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Saman, H., Raza, S.S., Uddin, S., and Rasul, K. (2020). Inducing Angiogenesis, a Key Step in Cancer Vascularization, and Treatment Approaches. Cancers, 12.","DOI":"10.20944\/preprints202004.0400.v1"},{"key":"ref_6","first-page":"156","article-title":"The Vascular Pattern of Tumors","volume":"41","author":"Lewis","year":"1927","journal-title":"Johns. Hopkins Hosp. Bull."},{"key":"ref_7","first-page":"891","article-title":"Vascularization of the Brown Pearce Rabbit Epithelioma Transplant as Seen in the Transparent Ear Chamber","volume":"42","author":"Ide","year":"1939","journal-title":"Am. J. Roentgenol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jnci\/6.1.73","article-title":"Vasculae Reactions of Normal and Malignant Tissues in Vivo. I. Vascular Reactions of Mice to Wounds and to Normal and Neoplastic Transplants","volume":"6","author":"Algire","year":"1945","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_9","first-page":"111","article-title":"Tumor Angiogenesis: Transfilter Diffusion Studies in the Hamster by the Transparent Chamber Technique","volume":"41","author":"Greenblatt","year":"1968","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/000331976601700507","article-title":"Choriocarcinoma: Vasodilatory Effect in the Hamster Cheek Pouch","volume":"17","author":"Ehrmann","year":"1966","journal-title":"Angiology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2115","article-title":"Angiogenesis: An Organizing Principle for Drug Discovery?","volume":"6","author":"Folkman","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrclinonc.2009.110","article-title":"Targeting Angiogenesis: Progress with Anti-VEGF Treatment with Large Molecules","volume":"6","author":"Grothey","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04483","article-title":"Angiogenesis as a Therapeutic Target","volume":"438","author":"Ferrara","year":"2005","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00001622-200001000-00015","article-title":"Is Angiogenesis Inhibition the Holy Grail of Cancer Therapy?","volume":"12","year":"2000","journal-title":"Curr. Opin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The Biology of VEGF and Its Receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/359843a0","article-title":"Vascular Endothelial Growth Factor Induced by Hypoxia May Mediate Hypoxia-Initiated Angiogenesis","volume":"359","author":"Shweiki","year":"1992","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1054\/bjoc.2000.1508","article-title":"Pre-Operative Serum Vascular Endothelial Growth Factor Can Select Patients for Adjuvant Treatment after Curative Resection in Colorectal Cancer","volume":"83","author":"Chin","year":"2000","journal-title":"Br. J. Cancer"},{"key":"ref_18","first-page":"1279","article-title":"Preoperative Serum Vascular Endothelial Growth Factor Can Predict Stage in Colorectal Cancer","volume":"4","author":"Kumar","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0093-7754(03)00124-6","article-title":"Inhibition of Vascular Endothelial Growth Factor in the Treatment of Colorectal Cancer","volume":"30","author":"Fernando","year":"2003","journal-title":"Semin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.leu.2404402","article-title":"The History of the Angiogenic Switch Concept","volume":"21","author":"Ribatti","year":"2007","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/74651","article-title":"Mechanisms of Angiogenesis and Arteriogenesis","volume":"6","author":"Carmeliet","year":"2000","journal-title":"Nat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.drup.2008.09.001","article-title":"Role of the Microenvironment in Tumor Growth and in Refractoriness\/Resistance to Anti-Angiogenic Therapies","volume":"11","author":"Shojaei","year":"2008","journal-title":"Drug Resist. Updat."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1038\/onc.2008.271","article-title":"The Tumor Microenvironment and Its Role in Promoting Tumor Growth","volume":"27","author":"Whiteside","year":"2008","journal-title":"Oncogene"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.gde.2010.10.008","article-title":"Vessel Abnormalization: Another Hallmark of Cancer? Molecular Mechanisms and Therapeutic Implications","volume":"21","author":"Cauwenberghs","year":"2011","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/sj.bjc.6604929","article-title":"Why Are Tumour Blood Vessels Abnormal and Why Is It Important to Know?","volume":"100","author":"Nagy","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1161\/ATVBAHA.107.161521","article-title":"Endothelial-Mural Cell Signaling in Vascular Development and Angiogenesis","volume":"29","author":"Gaengel","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1242\/jcs.000679","article-title":"Crosstalk between Neovessels and Mural Cells Directs the Site-Specific Expression of MT1-MMP to Endothelial Tip Cells","volume":"120","author":"Yana","year":"2007","journal-title":"J. Cell Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1161\/CIRCRESAHA.116.302855","article-title":"Endothelial Cell Metabolism in Normal and Diseased Vasculature","volume":"116","author":"Eelen","year":"2015","journal-title":"Circ. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrd3455","article-title":"Principles and Mechanisms of Vessel Normalization for Cancer and Other Angiogenic Diseases","volume":"10","author":"Carmeliet","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1158\/1535-7163.MCT-11-0555","article-title":"The Ubiquitin-Proteasome System Meets Angiogenesis","volume":"11","author":"Rahimi","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nm0603-677","article-title":"Regulation of Angiogenesis by Hypoxia: Role of the HIF System","volume":"9","author":"Pugh","year":"2003","journal-title":"Nat. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","article-title":"Normalization of the Vasculature for Treatment of Cancer and Other Diseases","volume":"91","author":"Goel","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1059796","article-title":"Targeting of HIF-\u03b1 to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation","volume":"292","author":"Jaakkola","year":"2001","journal-title":"Science"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","article-title":"Hypoxia-Inducible Factor 1 Is a Basic-Helix-Loop-Helix-PAS Heterodimer Regulated by Cellular O2 Tension","volume":"92","author":"Wang","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrc2868","article-title":"Targeting the Tumour Vasculature: Insights from Physiological Angiogenesis","volume":"10","author":"Chung","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_36","first-page":"4331","article-title":"Angiogenesis Revisited\u2013Role and Therapeutic Potential of Targeting Endothelial Metabolism","volume":"127","author":"Stapor","year":"2014","journal-title":"J. Cell Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1038\/oncsis.2015.14","article-title":"Compensatory Angiogenesis and Tumor Refractoriness","volume":"4","author":"Gacche","year":"2015","journal-title":"Oncogenesis"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.2479987","article-title":"Vascular Permeability Factor, an Endothelial Cell Mitogen Related to PDGF","volume":"246","author":"Keck","year":"1989","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1634\/theoncologist.2011-0113","article-title":"Bevacizumab Treatment for Advanced Breast Cancer","volume":"16","author":"Alvarez","year":"2011","journal-title":"Oncologist"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2174\/092986706777585059","article-title":"Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic","volume":"13","author":"Ranieri","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/ncponc0026","article-title":"Targeting Angiogenesis in Cancer: Clinical Development of Bevacizumab","volume":"1","author":"Kerr","year":"2004","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/08977199209023937","article-title":"The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies","volume":"7","author":"Kim","year":"1992","journal-title":"Growth Factors"},{"key":"ref_43","first-page":"4593","article-title":"Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jare.2017.06.006","article-title":"Anti-Angiogenic Agents for the Treatment of Solid Tumors: Potential Pathways, Therapy and Current Strategies\u2014A Review","volume":"8","author":"Alamoudi","year":"2017","journal-title":"J. Adv. Res."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Rajabi, M., and Mousa, S.A. (2017). The Role of Angiogenesis in Cancer Treatment. Biomedicines, 5.","DOI":"10.3390\/biomedicines5020034"},{"key":"ref_46","unstructured":"Roche, A.G. (2019). Avastin\/Bevacizumab Periodic Benefit-Risk Evaluation Report\/Periodic Safety Update Report, European Medicines Agency."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten Years of Anti-Vascular Endothelial Growth Factor Therapy","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1634\/theoncologist.12-3-356","article-title":"FDA Drug Approval Summary: Bevacizumab Plus FOLFOX4 as Second-Line Treatment of Colorectal Cancer","volume":"12","author":"Cohen","year":"2007","journal-title":"Oncologist"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.2005.10.017","article-title":"Bevacizumab in Combination with Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer","volume":"23","author":"Hurwitz","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_51","unstructured":"(2024, March 10). Drug Approval Package: Avastin (Bevacizum) NDA #125085, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/STN-125085_Avastin.cfm."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1200\/JCO.2008.17.7931","article-title":"Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients from Two Randomized Clinical Trials","volume":"27","author":"Kabbinavar","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)\/Leucovorin (LV) with FU\/LV Alone in Patients with Metastatic Colorectal Cancer","volume":"21","author":"Kabbinavar","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in Combination with Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"Giantonio","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1097\/JTO.0b013e3181da36f4","article-title":"Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel\/Carboplatin for Advanced Non-Small Cell Lung Cancer","volume":"5","author":"Sandler","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III Trial of Cisplatin plus Gemcitabine with Either Placebo or Bevacizumab as First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL","volume":"27","author":"Reck","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/annonc\/mdu098","article-title":"Maintenance Bevacizumab\u2013Pemetrexed after First-Line Cisplatin\u2013Pemetrexed\u2013Bevacizumab for Advanced Nonsquamous Nonsmall-Cell Lung Cancer: Updated Survival Analysis of the AVAPERL (MO22089) Randomized Phase III Trial","volume":"25","author":"Barlesi","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1200\/JCO.2012.42.3749","article-title":"Randomized Phase III Trial of Maintenance Bevacizumab with or without Pemetrexed after First-Line Induction with Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: AVAPERL (MO22089)","volume":"31","author":"Barlesi","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.lungcan.2020.11.020","article-title":"Erlotinib plus Bevacizumab vs Erlotinib Monotherapy as First-Line Treatment for Advanced EGFR Mutation-Positive Non-Squamous Non-Small-Cell Lung Cancer: Survival Follow-up Results of the Randomized JO25567 Study","volume":"151","author":"Yamamoto","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1111\/1759-7714.14541","article-title":"Erlotinib with or without Bevacizumab as a First-Line Therapy for Patients with Advanced Nonsquamous Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer: Exploratory Subgroup Analyses from the Phase II JO25567 Study","volume":"13","author":"Hosomi","year":"2022","journal-title":"Thorac. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","article-title":"Erlotinib plus Bevacizumab versus Erlotinib Alone in Patients with EGFR-Positive Advanced Non-Squamous Non-Small-Cell Lung Cancer (NEJ026): Interim Analysis of an Open-Label, Randomised, Multicentre, Phase 3 Trial","volume":"20","author":"Saito","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jtho.2021.09.014","article-title":"IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups with EGFR Mutations or Metastases in the Liver or Brain","volume":"17","author":"Nogami","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41416-021-01606-4","article-title":"Efficacy of First-Line Atezolizumab Combination Therapy in Patients with Non-Small Cell Lung Cancer Receiving Proton Pump Inhibitors: Post Hoc Analysis of IMpower150","volume":"126","author":"Hopkins","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1200\/JCO.2008.21.6630","article-title":"Independent Review of E2100: A Phase III Trial of Bevacizumab plus Paclitaxel versus Paclitaxel in Women with Metastatic Breast Cancer","volume":"27","author":"Gray","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/jco.2015.33.15_suppl.5505","article-title":"Retrospective Analysis of Candidate Predictive Tumor Biomarkers (BMs) for Efficacy in the GOG-0218 Trial Evaluating Front-Line Carboplatin\u2013Paclitaxel (CP) \u00b1 Bevacizumab (BEV) for Epithelial Ovarian Cancer (EOC)","volume":"33","author":"Birrer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A Phase 3 Trial of Bevacizumab in Ovarian Cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"Pautier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus Bevacizumab First-Line Maintenance in Ovarian Cancer: Final Overall Survival Results from the PAOLA-1\/ENGOT-Ov25 Trial","volume":"34","author":"Leary","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved Survival with Bevacizumab in Advanced Cervical Cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2165\/11203890-000000000-00000","article-title":"Bevacizumab: In Previously Treated Glioblastoma","volume":"70","author":"Moen","year":"2010","journal-title":"Drugs"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12325-011-0007-3","article-title":"AVAglio: Phase 3 Trial of Bevacizumab plus Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma Multiforme","volume":"28","author":"Chinot","year":"2011","journal-title":"Adv. Ther."},{"key":"ref_72","unstructured":"European Medicines Agency (2005). Avastin-Epar-Scientific-Discussion_en, European Medicines Agency."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of Bevacizumab after First Progression in Metastatic Colorectal Cancer (ML18147): A Randomised Phase 3 Trial","volume":"14","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in Combination with Oxaliplatin-Based Chemotherapy as First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study","volume":"26","author":"Saltz","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1007\/s12094-021-02568-y","article-title":"Patient Profiles as an Aim to Optimize Selection in the Second Line Setting: The Role of Aflibercept","volume":"23","year":"2021","journal-title":"Clin. Transl. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients with Metastatic Colorectal Cancer Previously Treated with an Oxaliplatin-Based Regimen","volume":"30","author":"Tabernero","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/14712598.2019.1600505","article-title":"Ramucirumab: The Long and Winding Road toward Being an Option for MCRC Treatment","volume":"19","author":"Debeuckelaere","year":"2019","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1080\/17512433.2019.1630272","article-title":"The Clinical Application of Fruquintinib on Colorectal Cancer","volume":"12","author":"Chen","year":"2019","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-019-0718-5","article-title":"Recent Advances on Anti-Angiogenesis Receptor Tyrosine Kinase Inhibitors in Cancer Therapy","volume":"12","author":"Qin","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"101912","DOI":"10.1016\/j.ctrv.2019.101912","article-title":"Molecular Insight of Regorafenib Treatment for Colorectal Cancer","volume":"81","author":"Arai","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0308-1","article-title":"Anti-Tumoral Activity of Single and Combined Regorafenib Treatments in Preclinical Models of Liver and Gastrointestinal Cancers","volume":"51","author":"Fondevila","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"102460","DOI":"10.1016\/j.ctrv.2022.102460","article-title":"Regorafenib in Combination with Immune Checkpoint Inhibitors for Mismatch Repair Proficient (PMMR)\/Microsatellite Stable (MSS) Colorectal Cancer","volume":"110","author":"Bregni","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO.2007.13.1193","article-title":"EPIC: Phase III Trial of Cetuximab plus Irinotecan after Fluoropyrimidine and Oxaliplatin Failure in Patients with Metastatic Colorectal Cancer","volume":"26","author":"Sobrero","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5217\/ir.2019.00080","article-title":"Novel Biomarkers for the Diagnosis and Prognosis of Colorectal Cancer","volume":"18","author":"Oh","year":"2020","journal-title":"Intest. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/14737140.2018.1428092","article-title":"The Role of Tumor Angiogenesis as a Therapeutic Target in Colorectal Cancer","volume":"18","author":"Battaglin","year":"2018","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","article-title":"Comprehensive Review of Targeted Therapy for Colorectal Cancer","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_87","unstructured":"Benson, A.B., Adam, M., Chen, Y.-J., Ciombor, K.K., Cohen, S., Deming, D., Garrido-Laguna, I., Grem, J.L., Buffett Cancer Center Paul Haste, P., and Randolph Hecht, J. (2024). NCCN Guidelines Version 1.2024 Colon Cancer Continue NCCN Guidelines Panel Disclosures, NCCN."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO Consensus Guidelines for the Management of Patients with Metastatic Colorectal Cancer","volume":"27","author":"Cervantes","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel\u2013Carboplatin Alone or with Bevacizumab for Non\u2013Small-Cell Lung Cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1200\/jco.2009.27.15_suppl.8039","article-title":"Final Safety Results of BO17704 (AVAiL): A Phase III Randomized Study of First-Line Bevacizumab (Bv) and Cisplatin\/Gemcitabine (CG) in Patients (Pts) with Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer (NSCLC)","volume":"27","author":"Hirsh","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/annonc\/mdq020","article-title":"Overall Survival with Cisplatin-Gemcitabine and Bevacizumab or Placebo as First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: Results from a Randomised Phase III Trial (AVAiL)","volume":"21","author":"Reck","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1097\/JTO.0b013e3181f49c22","article-title":"Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL)","volume":"5","author":"Leighl","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1200\/JCO.2012.47.9626","article-title":"PointBreak: A Randomized Phase III Study of Pemetrexed plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer","volume":"31","author":"Patel","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","article-title":"Erlotinib Alone or with Bevacizumab as First-Line Therapy in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer Harbouring EGFR Mutations (JO25567): An Open-Label, Randomised, Multicentre, Phase 2 Study","volume":"15","author":"Seto","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/PPO.0000000000000328","article-title":"Antiangiogenic Therapy in Colorectal Cancer","volume":"24","author":"Mody","year":"2018","journal-title":"Cancer J."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"Iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic Non-Small Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_98","unstructured":"Kristina Gregory, N., Lisa Hang, M., Aisner, D.L., Akerley, W., Bauman, J.R., Bruno, D.S., Chang, J.Y., Chirieac, L.R., DeCamp, M., and Desai, A.P. (2024). NCCN Guidelines Version 3.2024 Non-Small Cell Lung Cancer Continue NCCN Guidelines Panel Disclosures, NCCN."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jsps.2011.12.001","article-title":"The US FDAs Withdrawal of the Breast Cancer Indication for Avastin (Bevacizumab)","volume":"20","author":"Sasich","year":"2012","journal-title":"Saudi Pharm. J."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/cam4.574","article-title":"Survival among Patients with Advanced Renal Cell Carcinoma in the Pretargeted versus Targeted Therapy Eras","volume":"5","author":"Li","year":"2016","journal-title":"Cancer Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus Interferon Alfa-2a for Treatment of Metastatic Renal Cell Carcinoma: A Randomised, Double-Blind Phase III Trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF00390492","article-title":"Treatment of Advanced Renal Cell Cancer with Recombinant Interferon Alpha as a Single Agent and in Combination with Medroxyprogesterone Acetate\u2014A Randomized Multicenter Trial","volume":"114","author":"Porzsolt","year":"1988","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","article-title":"Phase III Trial of Bevacizumab plus Interferon Alfa-2a in Patients with Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival","volume":"28","author":"Escudier","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1200\/jco.2009.27.15_suppl.5020","article-title":"on behalf of the AVOREN Investigators. Final Results of the Phase III, Randomized, Double-Blind AVOREN Trial of First-Line Bevacizumab (BEV) + Interferon-A2a (IFN) in Metastatic Renal Cell Carcinoma (MRCC)","volume":"27","author":"Escudier","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","article-title":"Phase III Trial of Bevacizumab plus Interferon Alfa versus Interferon Alfa Monotherapy in Patients with Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206","volume":"28","author":"Rini","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","article-title":"Bevacizumab plus Interferon Alfa Compared with Interferon Alfa Monotherapy in Patients with Metastatic Renal Cell Carcinoma: CALGB 90206","volume":"26","author":"Rini","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus Bevacizumab versus Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma (IMmotion151): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.4143\/crt.2019.086","article-title":"Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients","volume":"51","author":"Choi","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1200\/JCO.2019.37.15_suppl.4501","article-title":"A Pilot Randomized Study Evaluating Nivolumab (Nivo) or Nivo + Bevacizumab (Bev) or Nivo + Ipilimumab (Ipi) in Patients with Metastatic Renal Cell Carcinoma (MRCC) Eligible for Cytoreductive Nephrectomy, Metastasectomy or Post-Treatment Biopsy (Bx)","volume":"37","author":"Gao","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Simion, L., Rotaru, V., Cirimbei, C., Stefan, D.C., Gherghe, M., Ionescu, S., Tanase, B.C., Luca, D.C., Gales, L.N., and Chitoran, E. (2023). Analysis of Efficacy-To-Safety Ratio of Angiogenesis-Inhibitors Based Therapies in Ovarian Cancer: A Systematic Review and Meta-Analysis. Diagnostics, 13.","DOI":"10.20944\/preprints202302.0030.v1"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Simion, L., Chitoran, E., Cirimbei, C., Stefan, D.-C., Neicu, A., Tanase, B., Ionescu, S.O., Luca, D.C., Gales, L., and Gheorghe, A.S. (2023). A Decade of Therapeutic Challenges in Synchronous Gynecological Cancers from the Bucharest Oncological Institute. Diagnostics, 13.","DOI":"10.3390\/diagnostics13122069"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Chitoran, E., Rotaru, V., Ionescu, S.-O., Gelal, A., Capsa, C.-M., Bohiltea, R.-E., Mitroiu, M.-N., Serban, D., Gullo, G., and Stefan, D.-C. (2024). Bevacizumab-Based Therapies in Malignant Tumors\u2014Real-World Data on Effectiveness, Safety, and Cost. Cancers, 16.","DOI":"10.3390\/cancers16142590"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab Combined with Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial","volume":"32","author":"Hilpert","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2018.36.15_suppl.5501","article-title":"A Phase III Randomized Controlled Trial of Secondary Surgical Cytoreduction (SSC) Followed by Platinum-Based Combination Chemotherapy (PBC), with or without Bevacizumab (B) in Platinum-Sensitive, Recurrent Ovarian Cancer (PSOC): A NRG Oncology\/Gynecologic Oncology Group (GOG) Study","volume":"36","author":"Coleman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final Overall Survival and Safety Analysis of OCEANS, a Phase 3 Trial of Chemotherapy with or without Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovarian Cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy with or Without Bevacizumab in Patients with Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard Chemotherapy with or without Bevacizumab for Women with Newly Diagnosed Ovarian Cancer (ICON7): Overall Survival Results of a Phase 3 Randomised Trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e478","DOI":"10.1016\/S1470-2045(15)00283-1","article-title":"Discordance between the Results and Conclusions of ICON7","volume":"16","author":"Gyawali","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e478","DOI":"10.1016\/S1470-2045(15)00311-3","article-title":"Discordance between the Results and Conclusions of ICON7\u2014Authors\u2019 Reply","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"TPS5606","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS5606","article-title":"OVARIO: The Phase 2, Single-Arm, Open-Label Study of Maintenance Therapy with Niraparib + Bevacizumab in Patients with Advanced Ovarian Cancer Following Response on Frontline Platinum-Based Chemotherapy","volume":"36","author":"Hope","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"TPS5607","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS5607","article-title":"ATALANTE (ENGOT-Ov29): A Randomized, Double-Blinded, Phase III Study of Atezolizumab versus Placebo in Patients with Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-Based Chemotherapy and Bevacizumab","volume":"36","author":"Kurtz","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"TPS5610","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS5610","article-title":"A Single-Arm, Phase II Study of Niraparib and Bevacizumab Maintenance Therapy in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)\/NIRVANA-R Trial","volume":"40","author":"Lee","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"TPS5611","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS5611","article-title":"AGO-OVAR 2.29 (ENGOT-Ov34): Atezolizumab in Combination with Bevacizumab and Chemotherapy versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer (ROC)","volume":"40","author":"Harter","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1634\/theoncologist.2002-0342","article-title":"Guidelines for the Treatment of Recurrent and Metastatic Cervical Cancer","volume":"7","author":"Friedlander","year":"2002","journal-title":"Oncologist"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"395","DOI":"10.6004\/jnccn.2015.0055","article-title":"Cervical Cancer, Version 2.2015","volume":"13","author":"Koh","year":"2015","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"iv72","DOI":"10.1093\/annonc\/mdx220","article-title":"Cervical Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"28","author":"Marth","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for Advanced Cervical Cancer: Final Overall Survival and Adverse Event Analysis of a Randomised, Controlled, Open-Label, Phase 3 Trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jamaoncol.2023.5410","article-title":"Pembrolizumab or Placebo Plus Chemotherapy with or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses from the KEYNOTE-826 Randomized Clinical Trial","volume":"10","author":"Tewari","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/PPO.0000000000000324","article-title":"Bevacizumab in Cervical Cancer: 5 Years After","volume":"24","author":"Pfaendler","year":"2018","journal-title":"Cancer J."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus Bevacizumab and Chemotherapy for Metastatic, Persistent, or Recurrent Cervical Cancer (BEATcc): A Randomised, Open-Label, Phase 3 Trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.annonc.2023.10.694","article-title":"VP5-2023: Primary Results from BEATcc (ENGOT-Cx10\/GEICO 68-C\/JGOG1084\/GOG-3030), a Randomised Phase III Trial of First-Line Atezolizumab (Atezo) Combined with a Platinum Doublet and Bevacizumab (Bev) for Metastatic (Stage IVB), Persistent or Recurrent Cervical Cancer (R\/M CC)","volume":"34","author":"Oaknin","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab Alone and in Combination with Irinotecan in Recurrent Glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus Radiotherapy\u2013Temozolomide for Newly Diagnosed Glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1002\/cncr.28259","article-title":"Glioblastoma Survival in the United States Improved after Food and Drug Administration Approval of Bevacizumab: A Population-Based Analysis","volume":"119","author":"Johnson","year":"2013","journal-title":"Cancer"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.ejca.2011.06.018","article-title":"Efficacy and Safety of Bevacizumab in Combination with Docetaxel for the First-Line Treatment of Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: Results from AVADO","volume":"47","author":"Pivot","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy with or without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"d7684","DOI":"10.1136\/bmj.d7684","article-title":"FDA Cancels Approval for Bevacizumab in Advanced Breast Cancer","volume":"343","author":"Tanne","year":"2011","journal-title":"BMJ"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1517\/14656566.2012.652088","article-title":"Avastin Withdrawal Symptoms","volume":"13","author":"Lynce","year":"2012","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"d4244","DOI":"10.1136\/bmj.d4244","article-title":"FDA Committee Votes to Withdraw Bevacizumab for Breast Cancer","volume":"343","author":"Lenzer","year":"2011","journal-title":"BMJ"},{"key":"ref_145","unstructured":"Benstetter, M., and Haubenreisser, S. (2011). European Medicines Agency Completes Its Review of Avastin Used in Breast Cancer Treatment, European Medicines Agency."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.biochi.2013.03.002","article-title":"Mechanisms of Resistance to Anti-Angiogenesis Therapies","volume":"95","author":"Giuliano","year":"2013","journal-title":"Biochimie"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/neuonc\/noy103","article-title":"VEGF-C Sustains VEGFR2 Activation under Bevacizumab Therapy and Promotes Glioblastoma Maintenance","volume":"20","author":"Michaelsen","year":"2018","journal-title":"Neuro Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/ijc.11059","article-title":"Altered Tumor Vessel Maturation and Proliferation in Placenta Growth Factor-Producing Tumors: Potential Relationship to Post-Therapy Tumor Angiogenesis and Recurrence","volume":"105","author":"Taylor","year":"2003","journal-title":"Int. J. Cancer"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/nbt1323","article-title":"Tumor Refractoriness to Anti-VEGF Treatment Is Mediated by CD11b+Gr1+ Myeloid Cells","volume":"25","author":"Shojaei","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/nature06348","article-title":"Bv8 Regulates Myeloid-Cell-Dependent Tumour Angiogenesis","volume":"450","author":"Shojaei","year":"2007","journal-title":"Nature"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccr.2008.12.004","article-title":"PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment","volume":"15","author":"Crawford","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1593\/neo.07871","article-title":"Plasticity in Tumor-Promoting Inflammation: Impairment of Macrophage Recruitment Evokes a Compensatory Neutrophil Response","volume":"10","author":"Pahler","year":"2008","journal-title":"Neoplasia"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1126\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:03:35Z","timestamp":1760029415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":152,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["cancers17071126"],"URL":"https:\/\/doi.org\/10.3390\/cancers17071126","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]}}}